BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32738331)

  • 1. A novel bile acid analog, A17, ameliorated non-alcoholic steatohepatitis in high-fat diet-fed hamsters.
    Wang Y; Zhu Y; Niu J; Deng Q; Guo S; Jiang H; Peng Z; Xue Y; Peng H; Xuan L; Pan G
    Toxicol Appl Pharmacol; 2020 Oct; 404():115169. PubMed ID: 32738331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obeticholic acid raises LDL-cholesterol and reduces HDL-cholesterol in the Diet-Induced NASH (DIN) hamster model.
    Briand F; Brousseau E; Quinsat M; Burcelin R; Sulpice T
    Eur J Pharmacol; 2018 Jan; 818():449-456. PubMed ID: 29155143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.
    Zhao L; Zhang C; Luo X; Wang P; Zhou W; Zhong S; Xie Y; Jiang Y; Yang P; Tang R; Pan Q; Hall AR; Luong TV; Fan J; Varghese Z; Moorhead JF; Pinzani M; Chen Y; Ruan XZ
    J Hepatol; 2018 Sep; 69(3):705-717. PubMed ID: 29705240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non-alcoholic steatohepatitis.
    Chen X; Li L; Liu X; Luo R; Liao G; Li L; Liu J; Cheng J; Lu Y; Chen Y
    Life Sci; 2018 Jun; 203():291-304. PubMed ID: 29709653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis.
    Hu YB; Liu XY; Zhan W
    Drug Des Devel Ther; 2018; 12():2213-2221. PubMed ID: 30038487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sesamin ameliorates nonalcoholic hepatic steatosis by inhibiting CD36-mediated hepatocyte lipid accumulation in vitro and in vivo.
    Bai YP; Zhang T; Hu ZY; Zhang Y; Wang DG; Zhou MY; Zhang Y; Zhang F; Kong X
    Biochem Pharmacol; 2024 Jun; 224():116240. PubMed ID: 38679210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway.
    Sun R; Yang N; Kong B; Cao B; Feng D; Yu X; Ge C; Huang J; Shen J; Wang P; Feng S; Fei F; Guo J; He J; Aa N; Chen Q; Pan Y; Schumacher JD; Yang CS; Guo GL; Aa J; Wang G
    Mol Pharmacol; 2017 Feb; 91(2):110-122. PubMed ID: 27932556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flaxseed Powder Attenuates Non-Alcoholic Steatohepatitis via Modulation of Gut Microbiota and Bile Acid Metabolism through Gut-Liver Axis.
    Yang C; Wan M; Xu D; Pan D; Xia H; Yang L; Sun G
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis.
    Li H; Xi Y; Xin X; Tian H; Hu Y
    Biomed Pharmacother; 2020 Apr; 124():109915. PubMed ID: 31986416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-chain fatty acid activates hepatocytes through CD36 mediated oxidative stress.
    Liu J; Yang P; Zuo G; He S; Tan W; Zhang X; Su C; Zhao L; Wei L; Chen Y; Ruan X; Chen Y
    Lipids Health Dis; 2018 Jul; 17(1):153. PubMed ID: 30016988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptome Analysis of Dual FXR and GPBAR1 Agonism in Rodent Model of NASH Reveals Modulation of Lipid Droplets Formation.
    Carino A; Marchianò S; Biagioli M; Fiorucci C; Zampella A; Monti MC; Morretta E; Bordoni M; Di Giorgio C; Roselli R; Ricci P; Distrutti E; Fiorucci S
    Nutrients; 2019 May; 11(5):. PubMed ID: 31117231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterozygous knockout of Bile salt export pump ameliorates liver steatosis in mice fed a high-fat diet.
    Okushin K; Tsutsumi T; Ikeuchi K; Kado A; Enooku K; Fujinaga H; Yamauchi N; Ushiku T; Moriya K; Yotsuyanagi H; Koike K
    PLoS One; 2020; 15(8):e0234750. PubMed ID: 32785220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alisol B Alleviates Hepatocyte Lipid Accumulation and Lipotoxicity via Regulating RARα-PPARγ-CD36 Cascade and Attenuates Non-Alcoholic Steatohepatitis in Mice.
    Zhao Z; Deng ZT; Huang S; Ning M; Feng Y; Shen Y; Zhao QS; Leng Y
    Nutrients; 2022 Jun; 14(12):. PubMed ID: 35745142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Farnesoid X Receptor Activation on Arachidonic Acid Metabolism, NF-kB Signaling, and Hepatic Inflammation.
    Gai Z; Visentin M; Gui T; Zhao L; Thasler WE; Häusler S; Hartling I; Cremonesi A; Hiller C; Kullak-Ublick GA
    Mol Pharmacol; 2018 Aug; 94(2):802-811. PubMed ID: 29743187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. G-protein-coupled bile acid receptor plays a key role in bile acid metabolism and fasting-induced hepatic steatosis in mice.
    Donepudi AC; Boehme S; Li F; Chiang JY
    Hepatology; 2017 Mar; 65(3):813-827. PubMed ID: 27351453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
    Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
    World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Park M; Yoo JH; Lee YS; Lee HJ
    Nutrients; 2019 Feb; 11(3):. PubMed ID: 30813654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An estrogen receptor β-selective agonist inhibits non-alcoholic steatohepatitis in preclinical models by regulating bile acid and xenobiotic receptors.
    Ponnusamy S; Tran QT; Thiyagarajan T; Miller DD; Bridges D; Narayanan R
    Exp Biol Med (Maywood); 2017 Mar; 242(6):606-616. PubMed ID: 28092182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters.
    Ge MX; Niu WX; Ren JF; Cai SY; Yu DK; Liu HT; Zhang N; Zhang YX; Wang YC; Shao RG; Wang JX; He HW
    Acta Pharmacol Sin; 2019 Jul; 40(7):895-907. PubMed ID: 30573812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.